Celldex Therapeutics Inc
CLDX21.910USD
-0.280-1.26%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.45BValor de mercado
PerdaP/L TTM
Mais detalhes de Celldex Therapeutics Inc Empresa
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Informações da empresa
Código da empresaCLDX
Nome da EmpresaCelldex Therapeutics Inc
Data de listagemMay 15, 1986
CEOMr. Anthony S. Marucci
Número de funcionários186
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 15
Endereço53 Frontage Road
CidadeHAMPTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08827
Telefone19084547120
Sitehttps://celldex.com/
Código da empresaCLDX
Data de listagemMay 15, 1986
CEOMr. Anthony S. Marucci
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Director
Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Investidores
Investidores
Proporção
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Tipos de investidores
Investidores
Proporção
Investment Advisor
45.68%
Hedge Fund
31.15%
Investment Advisor/Hedge Fund
29.65%
Research Firm
3.45%
Venture Capital
2.56%
Bank and Trust
0.33%
Pension Fund
0.31%
Individual Investor
0.27%
Insurance Company
0.04%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
419
75.39M
113.55%
-14.43M
2025Q1
437
75.31M
113.46%
-13.68M
2024Q4
437
75.05M
113.05%
-8.14M
2024Q3
429
73.28M
110.59%
-7.16M
2024Q2
432
71.48M
107.86%
-10.62M
2024Q1
419
71.32M
108.50%
+952.72K
2023Q4
406
62.72M
112.33%
-412.93K
2023Q3
403
52.10M
110.18%
-8.63M
2023Q2
410
51.84M
109.57%
-7.47M
2023Q1
419
51.38M
108.89%
-6.42M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wellington Management Company, LLP
8.35M
12.58%
-621.68K
-6.93%
Mar 31, 2025
Kynam Capital Management LP
6.50M
9.79%
+1.44M
+28.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.62M
6.97%
-29.87K
-0.64%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
5.85%
+441.18K
+12.80%
Mar 31, 2025
The Vanguard Group, Inc.
3.89M
5.85%
+16.44K
+0.42%
Mar 31, 2025
Eventide Asset Management, LLC
3.75M
5.66%
+1.53K
+0.04%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.35M
5.05%
-144.43K
-4.13%
Mar 31, 2025
Commodore Capital LP
3.35M
5.05%
+150.00K
+4.69%
Apr 03, 2025
Bellevue Asset Management AG
3.07M
4.63%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.81M
4.23%
-428.60K
-13.25%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
Nuveen ESG Small-Cap ETF
0.11%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
T Rowe Price Small-Mid Cap ETF
0.1%
iShares Russell 2000 Value ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.9%
SPDR S&P Biotech ETF
Proporção0.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.21%
Nuveen ESG Small-Cap ETF
Proporção0.11%
Fidelity Fundamental Small-Mid Cap ETF
Proporção0.11%
T Rowe Price Small-Mid Cap ETF
Proporção0.1%
iShares Russell 2000 Value ETF
Proporção0.1%
Avantis US Small Cap Equity ETF
Proporção0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.07%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
